Patents Examined by Lianko G Garyu
  • Cartilage replacement compositions and methods
    Patent number: 11130799
    Abstract: Described are compositions and methods for cartilage replacement. Also described are collagen scaffolds comprising the composition described herein.
    Type: Grant
    Filed: March 29, 2020
    Date of Patent: September 28, 2021
    Assignee: INNOVATIVE ORTHOPEDICS, LLC
    Inventor: Pablo Antonio Betancourt Alexander
  • Dual ACE C-domain/NEP inhibitors
    Patent number: 11129805
    Abstract: A superior dual ACE/NEP inhibitor is a combination that selectively targets the ACE C-domain in addition to inhibiting NEP. Such a dual ACE C-domain/NEP inhibitor can be used in the treatment of diverse cardiovascular diseases, including hypertension and heart failure.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: September 28, 2021
    Assignee: ANGIODESIGN (UK) LIMITED
    Inventors: Edward D. Sturrock, Mario R. W. Ehlers
  • Fusion polypeptides comprising one or more inclusion body tags, methods and uses
    Patent number: 11124555
    Abstract: A fusion polypeptide, comprising an inclusion body tag fused to at least one polypeptide of interest, is provided. The inclusion body tag comprises an inclusion body forming (IBF) amino acid sequence selected from X14X15AX17X18X19GLTVA GMLG and sequences having at least 71% identity thereto. Also provided are inclusion bodies comprising the fusion polypeptide, as well as nucleic acids, expression vectors, host cells and methods for its production.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: September 21, 2021
    Assignee: ABERA BIOSCIENCE AB
    Inventors: Wouter Simon Petrus Jong, Joen Luirink
  • Therapeutic peptides
    Patent number: 11111271
    Abstract: Provided herein are peptides and peptide analogs and methods of treating a metabolic disease, e.g., obesity, diabetes, methods of treating cancer, methods of treating a liver disease, and methods of modulating fatty acid metabolism.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: September 7, 2021
    Assignee: COHBAR, INC.
    Inventors: Kenneth C. Cundy, Kent K. Grindstaff, Remi Magnan, Wendy Luo, Yongjin Yao, Liang Zeng Yan
  • Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
    Patent number: 11065231
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4); the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hppel-Lindau, cereblon, ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: July 20, 2021
    Assignee: ARVINAS OPERATIONS, INC.
    Inventors: Andrew P. Crew, Erika Araujo
  • Compositions and methods for treating or preventing viral infections
    Patent number: 11065298
    Abstract: Compositions and methods disclosed herein may be used for treating or preventing viral infections. The compositions may be administered orally to subjects in need of preventative or therapeutic treatment and/or the compositions may be used to disinfect surfaces in order to prevent or limit the spread of disease through surface contact.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: July 20, 2021
    Inventors: Chanda Zaveri, Meng Teng Lim
  • Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with C5 polymorphism
    Patent number: 11052129
    Abstract: The present invention relates to methods of treating or preventing a complement-mediated disease and/or disorder in a subject with a complement C5 polymorphism, including administering to a subject in need thereof a therapeutically or prophylactically effective amount of an agent that a) inhibits the classical complement pathway, the alternative complement pathway and the lectin complement pathway; and/or b) inhibits eicosanoid activity. The invention also relates to methods of identifying patient populations with C5 polymorphisms that are treatable with specific agents that a) inhibit the classical complement pathway, the alternative complement pathway and the lectin complement pathway; and/or b) inhibit eicosanoid activity.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: July 6, 2021
    Assignee: Volution Immuno Pharmaceuticals SA
    Inventor: Wynne H. Weston-Davies
  • Delivery of Nrf2 as therapy for protection against reactive oxygen species
    Patent number: 11053291
    Abstract: The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or inflammation, including ocular inflammation. In some embodiments, the methods comprise administering an expression vector that delivers a secretable and cell penetrating Nrf2 to a subject in need thereof.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: July 6, 2021
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Cristhian J. Ildefonso, Alfred S. Lewin, Qiuhong Li
  • Treatment of a subtype of ASD
    Patent number: 11040117
    Abstract: The present invention is directed to a pharmaceutical composition comprising an Nrf2-inhibitor. Likewise, the present invention is directed to a pharmaceutical composition for use in the treatment of ASD in a patient, comprising: determining whether the patient suffers from ASD subtype 1 and administering a therapeutically effective amount of an Nrf2-inhibitor if the patients suffers from ASD subtype 1, wherein determining whether the patient suffers from ASD subtype 1 comprises administering the patient an Nrf2-activator and identifying the patient as suffering from ASD subtype 1 if he shows a negative response.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: June 22, 2021
    Assignee: Stalicla S.A.
    Inventor: Lynn Durham
  • Peptides capable of reactivating p53 mutants
    Patent number: 11028127
    Abstract: The invention provides peptides that can reactivate p53 mutants efficiently and specifically, as well as methods that allow the identification, selection and isolation of such peptides, in a precise, cost and time effective manner. In particular, there are provided mutant p53 reactivating peptides that can restore the native wild type p53 folding, and hence the tumor suppressor activity, to the mutant p53 protein. Such peptides are useful for treating various conditions and diseases in which p53 is mutated.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: June 8, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Moshe Oren, Varda Rotter, Perry Tal
  • Peptibodies, compositions thereof, and methods of treating atrial fibrillation
    Patent number: 11014971
    Abstract: Described herein are peptibodies that can contain a TertiapinQ peptide, formulations thereof, and uses thereof. In some embodiments, the peptibody can include a first monomer and a second monomer, wherein each monomer can include an Fc polypeptide, a first TertiapinQ peptide, wherein the N-terminus of the first TertiapinQ peptide can be linked to the C-terminus of the Fc polypeptide via a first linker, and wherein the first monomer and the second monomer can be attached via a disulfide bridge between the Fc polypeptide of the first monomer and the Fc polypeptide of the second monomer. The compositions and formulations thereof can be used to treat atrial fibrillation.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: May 25, 2021
    Assignee: University of South Florida
    Inventors: Sami Fouad Noujaim, Michael Teng
  • Peptide combinations and uses thereof for treating grass allergy
    Patent number: 11013781
    Abstract: The invention relates to combinations of peptides derived from a portion of an amino sequence of a grass pollen allergen, e.g. the allergens Phl p 1, Phl p 2, Phl p 3, Phl p 4 and/or Phl p 5, or a peptide variant thereof. Such peptides comprise at least one T cell epitope mid a high number of patients in a worldwide population will have HLA Class II alleles with the potential to bind the peptides of the peptide combinations. The invention also relates to the use of such peptide combinations in relieving an immune response caused by grass pollen species.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: May 25, 2021
    Assignees: ALK-ABELLÓ AS, LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Claus Lundegaard, Shashank Gupta, Bjoern Peters, Susanne Sønderkær, Jens Brimnes, Peter Adler Würtzen, Helene Henmar, Thomas Christian Mygind, Lise Lund Mærkedahl, Alessandro Sette
  • Modifications and uses of conotoxin peptides
    Patent number: 11014970
    Abstract: The present disclosure describes analog conotoxin peptides of the ?-conotoxin peptide RgIA. These analog conotoxin peptides block the ?9?10 subtype of the nicotinic acetylcholine receptor (nAChR) and can be used for treating pain and inflammation including inflammatory pain, cancer related pain, and neuropathic pain. The RgIA analogs described in the present invention include a variety of sequence modifications and chemical modifications that are introduced to improve the drug-like characteristics of RgIA analogs and thereby increase their therapeutic value.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: May 25, 2021
    Assignee: Kineta Chronic Pain, LLC
    Inventor: Jeffrey Jerard Posakony
  • Polypeptide exhibiting affinity to antibodies forming non-native three-dimensional structure
    Patent number: 11008365
    Abstract: The present invention relates to a novel polypeptide having affinity for proteins partially including a CH1-CL domain forming a non-native three-dimensional structure and capable of being suitably used for detecting, immobilizing, or removing these proteins and relates to use of the polypeptide. Specifically, disclosed are a polypeptide consisting of an amino acid sequence represented by any one of the following formulas 1 to 3: (1) P-Q-x-I-x-L-x-[IL]-[NT]-[YW] (SEQ ID NO: 1), (2) Y-D-P-E-T-G-T-W-P-Q-x-I-x-L-x-[IL]-[NT]-[YW] (SEQ ID NO: 4), and (3) P-N-S-G-G-G-G-S-Y-D-P-E-T-G-T-W-P-Q-x-I-x-L-x-[IL]-[NT]-[YW] (SEQ ID NO: 7) (wherein x represents an amino acid residue; and brackets represent any one of the amino acid residues within the brackets), and a method of using the polypeptide to detect, purify, or remove a protein partially including a CH1-CL domain forming a non-native three-dimensional structure.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: May 18, 2021
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Hideki Watanabe, Shinya Honda
  • Fasting mimicking and enhancing diet for treating hypertension and lipid disorders
    Patent number: 11000057
    Abstract: Methods for lowering hypertension, elevated total cholesterol, elevated glucose and insulin, elevated IGF-1, elevated triglyceride levels, and/or elevated CRP levels, and elevated liver fat without negatively affecting or lowering the levels of these markers/factors in subjects with already low levels of these markers are provided. A method for elevating stem cells and regeneration and anti-inflammatory agents is also provided. Finally, a method for treating metabolic syndrome is also provided. A hypocaloric or calorie free diet or a fasting mimicking diet is administered for a first time period to the subject to reduce blood pressure or the levels of the above markers/risk factors for aging and age-related diseases.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: May 11, 2021
    Assignee: University of Southern California
    Inventors: Valter D. Longo, Sebastian Brandhorst, Min Wei
  • Long-acting palmitic acid-conjugated GnRH derivative, and pharmaceutical composition containing same
    Patent number: 10994018
    Abstract: The present invention relates to a novel long-acting palmitic acid-conjugated gonadotrophin-releasing hormone (GnRH) derivative and a pharmaceutical composition containing the same. A GnRH derivative of the present invention is expected to greatly contribute, through excellent bioavailability and increased half-life in blood, to the reduction in drug dosing frequency and dosage and the like in the treatment of sex hormone-dependent diseases. Particularly, the GnRH derivative can overcome the disadvantages of existing GnRH sustained-release preparations, which have the side effects of residual feeling and pain at the injection site.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: May 4, 2021
    Assignee: NOVEL PHARMA INC.
    Inventor: Dong Kyu Jin
  • Treatment and prevention of remote ischemia-reperfusion injury
    Patent number: 10973891
    Abstract: The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitory to an individual.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: April 13, 2021
    Assignees: CSL Behring GmbH, Universitaet Bern
    Inventors: Rolf Spirig, Sylvia Miescher, Marc Nolte, Claudia Duehrkop-Sisewitsch, Robert Rieben
  • Method of treatment
    Patent number: 10973874
    Abstract: The present disclosure relates to the control of fungal infection of horn-like envelopes covering dorsal and terminal phalanges in humans and animals and related cerebral protrusions in animals as well as keratin comprising material on surfaces of humans and animals. Agents and natural and synthetic formulations and extracts useful for the control of fungal infection of these envelopes and related protrusions and keratin comprising material are also encompassed by the subject disclosure. In an embodiment, the present disclosure teaches the treatment of fungal infection of nails and in particular onychomycosis in humans.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: April 13, 2021
    Assignee: Hexima Limited
    Inventors: Nicole Louise van der Weerden, Marilyn Anne Anderson
  • Methods and compositions for treating diseases and conditions associated with gonadotropin releasing hormone receptor
    Patent number: 10975124
    Abstract: The disclosure is directed in non-limiting embodiments to compounds, compositions, and methods of treating conditions and diseases associated with activation of the gonadotropin GnRH receptor (GnRHR), particularly those involving GnRHR activating autoantibodies (GnRHR AAbs). In one non-limiting embodiment, the disease is Polycystic Ovary Syndrome (PCOS). The therapeutic compounds in at least certain embodiments include peptides which at least partially comprise D-amino acids, such as retro-inverso D-amino acid (RID) peptides, which are able to bind with high affinity to GnRHR AAbs.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: April 13, 2021
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: David Charles Kem, Xichun Yu, Hongliang Li, LaTasha B. Craig
  • Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
    Patent number: 10967038
    Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor (poly-)peptides, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory eye diseases, such as inflammatory diseases of the blephara, conjunctiva, cornea, sclera, the vitreous body, uvea, ciliary body, choroid, orbital bone, lacrimal gland, or iris, in particular wherein the inflammatory disease is selected from hordeolum, chalazion, conjunktivitis, keratitis, scieritis, episcleritis, endophthalmitis, panophtalmitis, irititis, uveitis, cyclitis, chorioiditis, orbital phlegmon, and myositis of the eye muscle etc.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: April 6, 2021
    Assignee: Xigen Inflammation Ltd.
    Inventors: Jean-Marc Combette, Catherine Deloche, Claire Abadie